BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Addex Therapeutics 

12, Chemin Des Aulx
1228 Plan-les-Ouates
Geneva      Switzerland
Phone: 41-22-884-1555 Fax: 41-22-884-1556


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





 Company News
Addex Therapeutics (ADXN.SW)-Janssen Pharmaceutical Inc. Team's Depression Drug Fails In Phase 2a Trial 2/10/2014 7:32:27 AM    More...
Addex Therapeutics (ADXN.SW) and National Institute on Drug Abuse (NIDA) Enter Collaboration to Advance ADX71441 & ADX88178 in Drug Abuse and Addiction 11/4/2013 9:39:09 AM    More...
Addex Therapeutics (ADXN.SW) Licensee Completes Enrollment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 10/29/2013 9:30:12 AM    More...
Addex Therapeutics (ADXN.SW) ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease 10/3/2013 9:53:37 AM    More...
Addex Therapeutics (ADXN.SW) First Half 2013 Financial Results 9/17/2013 9:28:17 AM    More...
Chronic Treatment With Addex Therapeutics (ADXN.SW) Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 9/4/2013 11:56:58 AM    More...
Addex Therapeutics (ADXN.SW) Raises $3.4 Million in a Private Placement to International Institutional Investors 8/9/2013 8:31:07 AM    More...
Addex Therapeutics (ADXN.SW) Terminates 17 Out of 19 Employees in Restructuring, CEO Steps Down 5/31/2013 10:55:33 AM    More...
Addex Therapeutics (ADXN.SW) Validates Potential Efficacy Biomarker for Phase 1 Trial of Its GABA-B Positive Allosteric Modulator, ADX71441 5/21/2013 11:13:51 AM    More...
Addex Therapeutics (ADXN.SW) Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study 5/1/2013 11:52:38 AM    More...
12345678910...

//-->